No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use

Life Sciences

Volumn 66, Issue 12, 2000, Pages 1079-1083

  Wenk, Gary L ^a,c   Quack, Guenter ^b   Moebius, Hans Joerg ^b   Danysz, Wojciech ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b MERZ PHARMACEUTICALS GMBH   (Germany)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Acetylcholinesterase inhibition; Alzheimer's disease; Clinical therapy; Dementia; Memantine

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; INTELIGEN; MEMANTINE; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; CHOLINESTERASE INHIBITION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; ENZYME ACTIVITY; MALE; NONHUMAN; RAT;

ACETYLCHOLINESTERASE; ANIMALS; CHOLINESTERASE INHIBITORS; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; GALANTAMINE; INDANS; MALE; MEMANTINE; PIPERIDINES; RATS; RATS, INBRED F344; TACRINE;

EID: 0034635589     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(00)00411-2     Document Type: Article

References (16)

1. 1. E.K. Perry, B.E. Tomlinson, G. Blessed, K. Bergman, P.H. Gibson and R.H., Perry, Br. Med. J. 2 1456-1459 (1978).
2. 2. M., Farlow, S.I. Gracon, L.A. Hershey, K.W. Lewis, C.H. Sadowsky and J.A. Dolan-Ureno, Jama 268 2523-2529 (1992).
3. 3. S.L. Rogers, R.S. Doody, R.C. Mohs and L.T. Friedhoff, Arch. Int. Med. 158 1021-1031 (1998).
4. 4. G.L. Wenk, Neurobiol. Learn. Mem. 67 85-95 (1997).
5. 5. J.T. Greenamyre and A.B. Young, Neurobiol. Aging 10 593-602 (1989).
6. 6. C.G. Parsons, W. Danysz and G. Quack, Neuropharmacol. 38 735-767 (1999).
7. 7. R. Gortelmeyer and H. Erbler, Arzeneim-Forsch/Drug Res. 42 904-913 (1992).
8. 8. B. Winblad and N. Poritis, Int. J. Geriat. Psychiatry 14 135-146 (1999).
9. 9. J. Kornhuber, J. Bormann, M. Hubers, K. Rusche and P. Riederer, Eur. J. Pharmacol. 206 297-311 (1991).
10. 10. R.C. Gupta and W.L. Kadel, J. Toxicol. Environ. Hlth. 28 111-122 (1989).
11. 11. R.C. Gupta and W.L. Kadel, Drug Dev. Res. 24 329-341 (1991).
12. 12. M.J. McLean, R.C. Gupta, W.D. Dettbarn and A.W. Wamil, Toxicol. Appl. Pharmacol. 112 95-103 (1992).
13. 13. A. Galli and F. Mori, J. Pharm. Pharmacol. 48 71-76 (1996).
14. 14. G.L. Ellman, K.D. Courtney, J.V. Andres and R.M. Featherstone, Biochem. Pharmacol. 7 88-95 (1961).
15. 15. C.A. Barnes, W. Danysz and C.G. Parsons, Eur. J. Neurosci. 8 65-571 (1996).
16. 16. W. Zajaczkowski, T. Frankiewicz, C.G. Parsons and W. Danysz, Neuropharm. 36 961-971 (1997).